39.30
0.33 (0.85%)
| Penutupan Terdahulu | 38.97 |
| Buka | 39.20 |
| Jumlah Dagangan | 1,044,500 |
| Purata Dagangan (3B) | 822,321 |
| Modal Pasaran | 3,566,310,400 |
| Harga / Jualan (P/S) | 6.30 |
| Harga / Buku (P/B) | 14.33 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 30 Apr 2025 - 5 May 2025 |
| Margin Keuntungan | -101.60% |
| Margin Operasi (TTM) | -74.16% |
| EPS Cair (TTM) | -6.29 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 29.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 346.94% |
| Nisbah Semasa (MRQ) | 2.37 |
| Aliran Tunai Operasi (OCF TTM) | -414.19 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -207.49 M |
| Pulangan Atas Aset (ROA TTM) | -22.37% |
| Pulangan Atas Ekuiti (ROE TTM) | -211.71% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menurun |
| Biotechnology (Global) | Bercampur | Menurun | |
| Stok | Ultragenyx Pharmaceutical Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 1.25 |
|
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 3.45% |
| % Dimiliki oleh Institusi | 97.20% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 136.00 (Canaccord Genuity, 246.06%) | Beli |
| Median | 116.00 (195.17%) | |
| Rendah | 65.00 (Morgan Stanley, 65.39%) | Beli |
| Purata | 107.67 (173.97%) | |
| Jumlah | 6 Beli | |
| Harga Purata @ Panggilan | 41.12 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Morgan Stanley | 09 May 2025 | 65.00 (65.39%) | Beli | 39.30 |
| JP Morgan | 27 Mar 2025 | 117.00 (197.71%) | Beli | 38.89 |
| Piper Sandler | 17 Mar 2025 | 115.00 (192.62%) | Beli | 39.64 |
| Cantor Fitzgerald | 26 Feb 2025 | 118.00 (200.25%) | Beli | 41.62 |
| Canaccord Genuity | 18 Feb 2025 | 136.00 (246.06%) | Beli | 43.62 |
| HC Wainwright & Co. | 18 Feb 2025 | 95.00 (141.73%) | Beli | 43.62 |
| 14 Feb 2025 | 95.00 (141.73%) | Beli | 42.49 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |